Axa S.A. Sells 856 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Axa S.A. decreased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.3% during the 2nd quarter, Holdings Channel reports. The fund owned 36,764 shares of the company’s stock after selling 856 shares during the quarter. Axa S.A.’s holdings in Harmony Biosciences were worth $1,109,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the company. Hedeker Wealth LLC acquired a new position in shares of Harmony Biosciences in the 1st quarter valued at $2,627,000. LSV Asset Management grew its stake in Harmony Biosciences by 346.5% in the first quarter. LSV Asset Management now owns 335,146 shares of the company’s stock valued at $11,254,000 after acquiring an additional 260,093 shares during the period. Franklin Resources Inc. bought a new stake in shares of Harmony Biosciences in the fourth quarter worth about $876,000. Rice Hall James & Associates LLC raised its position in shares of Harmony Biosciences by 42.1% during the second quarter. Rice Hall James & Associates LLC now owns 80,512 shares of the company’s stock worth $2,429,000 after purchasing an additional 23,867 shares during the period. Finally, Marshall Wace LLP lifted its holdings in shares of Harmony Biosciences by 145.4% during the 2nd quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after purchasing an additional 181,092 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $52.00 target price on shares of Harmony Biosciences in a research note on Tuesday, September 24th. Citigroup began coverage on shares of Harmony Biosciences in a report on Friday, June 21st. They set a “buy” rating and a $48.00 price objective on the stock. Finally, UBS Group assumed coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Harmony Biosciences Stock Performance

Shares of HRMY opened at $39.24 on Wednesday. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $40.60. The firm has a fifty day simple moving average of $35.86 and a 200 day simple moving average of $32.60. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of 17.32, a PEG ratio of 0.77 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.24. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The company had revenue of $172.80 million during the quarter, compared to analysts’ expectations of $172.53 million. During the same quarter last year, the company earned $0.56 EPS. Harmony Biosciences’s revenue for the quarter was up 28.8% compared to the same quarter last year. Research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.